Announcements Trials
Browse Landscape

Status

No longer available 1

Sponsor Class

OTHER 1

Study Type

Interventional 73Observational 1Expanded_access 1

Sponsor

Cancer Type

Sarcoma 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Gastrointestinal Stromal Tumors 1

Interventions

regorafenib 3Sunitinib 2Ramucirumab 2Oxaliplatin 2Fluorouracil 2zenocutuzumab 1zanidatamab 1ulixertinib 1trifluridine tipiracil drug combination 1sodium thiosulfate 1selpercatinib 1ripretinib 1peginterferon alfa-2a 1pegilodecakin 1onvansertib 1omburtamab I-131 1guselkumab 1futibatinib 1derazantinib 1balstilimab 1avapritinib 1Tenofovir 1Taxes 1Proton Pump Inhibitors 1Paclitaxel 1Melphalan 1Leucovorin 1Laparoscopy 1Imatinib Mesylate 1IMM-101 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Expanded_access × Everolimus × Gastrointestinal × Clear all
NCT03493152 2025-05-28

Expanded Access to Everolimus, for an Individual Patient With GIST (Gastrointestinal Stromal Tumors)(CTMS#18-0019)

The University of Texas Health Science Center at San Antonio

No longer available
GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡